Zetia Real-World Response Rate: What Patients Actually Experience

Ezetimibe is a cholesterol absorption inhibitor, not a statin [1]. It blocks the intestinal sterol transporter NPC1L1, reducing cholesterol delivery to the liver and increasing LDL receptor clearance from the blood [1]. The label's recommended dose is 10 mg once daily, with or without food [1]. This page covers single-ingredient ezetimibe; ezetimibe/simvastatin and bempedoic acid/ezetimibe are separate products with their own labels.

What does 'response rate' mean for ezetimibe?

A responder rate is usually the percentage of patients who reach a threshold, such as a specific LDL cholesterol drop or a target level. The trial tables in the Zetia label report the mean percentage change from untreated baseline for each treatment group [1].

How much does ezetimibe lower LDL cholesterol?

In two multicenter, double-blind, placebo-controlled 12-week trials in 1,719 adults with primary hyperlipidemia, pooled results were: LDL cholesterol -18% with ezetimibe 10 mg (n=1,288) versus +1% with placebo (n=431); total cholesterol -13% versus 0%; apolipoprotein B -16% versus -2%; non-HDL cholesterol -16% versus +1% [1]. Maximal to near maximal response was generally reached within 2 weeks [1]. The label says the LDL cholesterol reduction was consistent across age, sex and baseline LDL cholesterol [1].

In an 8-week trial of 769 patients already on a statin and above their LDL goal, adding ezetimibe lowered LDL cholesterol by 25% versus 4% with placebo added; total cholesterol fell 17% versus 2% [1]. When ezetimibe was started at the same time as atorvastatin 10 mg, LDL cholesterol fell 53% with the combination versus 37% with atorvastatin alone [1].

When to check LDL cholesterol

The label says to assess LDL cholesterol when clinically appropriate, as early as 4 weeks after starting ezetimibe [1]. In a 2-week trial of 18 patients, ezetimibe inhibited intestinal cholesterol absorption by 54% compared with placebo [1].

What patients experienced in the trials

In 10 placebo-controlled monotherapy trials (2,396 patients on ezetimibe 10 mg and 1,159 on placebo, median 12 weeks), adverse reactions reported in at least 2% of ezetimibe patients and more often than placebo were: upper respiratory tract infection 4.3% versus 2.5%; diarrhea 4.1% versus 3.7%; arthralgia 3.0% versus 2.2%; sinusitis 2.8% versus 2.2%; pain in extremity 2.7% versus 2.5%; fatigue 2.4% versus 1.5%; influenza 2.0% versus 1.5% [1].

With a statin (11,308 patients on ezetimibe plus a statin and 9,361 on a statin alone, median 8 weeks), the rates were: nasopharyngitis 3.7% versus 3.3%; myalgia 3.2% versus 2.7%; arthralgia 2.6% versus 2.4%; diarrhea 2.5% versus 2.2%; back pain 2.4% versus 2.3% [1]. Consecutive liver transaminase rises of at least 3 times the upper limit of normal occurred in 1.3% with ezetimibe plus a statin versus 0.4% with a statin alone [1].

Postmarketing reports, for which frequency cannot be estimated, include myopathy and rhabdomyolysis, hepatitis, cholelithiasis, cholecystitis, elevated liver enzymes, thrombocytopenia, pancreatitis, hypersensitivity including anaphylaxis and angioedema, depression, dizziness, paresthesia, headache and erythema multiforme [1]. Most postmarketing rhabdomyolysis patients were taking a statin or another agent such as a fibrate [1].

Does ezetimibe reduce heart attacks?

The Zetia label has no cardiovascular risk-reduction indication and does not mention the IMPROVE-IT trial [1]. The label's approved purpose is lowering LDL cholesterol and, in homozygous sitosterolemia, lowering sitosterol and campesterol [1].

IMPROVE-IT tested a combination, not ezetimibe alone. It enrolled 18,144 patients hospitalized for acute coronary syndrome within the previous 10 days and compared simvastatin 40 mg plus ezetimibe 10 mg with simvastatin 40 mg plus placebo [2]. Median follow-up was 6 years; mean on-treatment LDL cholesterol was 53.7 mg/dL versus 69.5 mg/dL [2]. The primary composite endpoint (cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization at least 30 days after randomization, or nonfatal stroke) occurred in 32.7% versus 34.7% at 7 years, an absolute difference of 2.0 percentage points, hazard ratio 0.936 (95% CI 0.89 to 0.99; p=0.016) [2]. Muscle, gallbladder, hepatic adverse effects and cancer were similar between groups [2].

What the label says to watch for

The single-ingredient Zetia label has no boxed warning [1]. Its Warnings and Precautions section covers liver enzyme abnormalities and skeletal muscle effects, and says that when ezetimibe is used with a statin, fenofibrate or another LDL-lowering therapy, that partner product's risks apply [1]. The label says to perform liver enzyme testing as clinically indicated and to consider withdrawing ezetimibe if ALT or AST increases of at least 3 times the upper limit of normal persist [1]. It says ezetimibe may cause myopathy and rhabdomyolysis, and that if myopathy is suspected, ezetimibe and other concomitant medications should be discontinued as appropriate [1].

With fenofibrate, both drugs can increase cholesterol excretion into bile; cholecystectomy rates were 0.6% with fenofibrate alone versus 1.7% with fenofibrate plus ezetimibe, and the label says gallbladder studies are indicated if cholelithiasis is suspected [1]. The label says coadministration with fibrates other than fenofibrate is not recommended [1]. Cyclosporine and ezetimibe raise each other's concentrations, and the label says to monitor cyclosporine concentrations [1]. Cholestyramine lowers ezetimibe exposure; the label says to take ezetimibe at least 2 hours before or 4 hours after a bile acid sequestrant [1]. The label does not recommend ezetimibe in moderate or severe hepatic impairment (Child-Pugh B or C) [1]. It is contraindicated in patients with known hypersensitivity to ezetimibe or any excipient, and, when used with a statin or fenofibrate, in patients for whom that partner drug is contraindicated [1].